Minimed IPO prices $20 per share

Minimed IPO prices $20 per share

MiniMed Group, the diabetes business unit of Medtronic (NYSE: MDT), has priced its initial public offering (IPO) at $25 to $28 per share for 28,000,000 shares, with underwriters retaining a 30-day option to purchase up to 4,200,000 additional shares according to reports. The offering, which launched its roadshow on February 24, 2026, is expected to generate gross proceeds of up to $784 million if priced at the top of the range as reported. Medtronic will retain approximately 90.03% ownership post-IPO (or 88.70% if the over-allotment is exercised), with proceeds allocated to repay intercompany debt, fund corporate operations, and provide consideration for transferred assets according to filings.

MiniMed reported $2.7 billion in revenue for fiscal 2025 but incurred a net loss of $198 million during the same period according to financial data. The company differentiates itself as the sole provider of integrated diabetes therapy solutions, combining insulin pumps, continuous glucose monitors (CGMs), and automation software as detailed. Recent product developments include the FDA-approved Simplera Sync CGM and the MiniMed 780G pump, alongside upcoming devices like the smaller-form-factor MiniMed Flex and a patch pump, MiniMed Fit according to product updates.

The IPO, managed by underwriters including Goldman Sachs, BofA Securities, and Citigroup, will list shares on Nasdaq under the ticker "MMED" as announced. A Form S-1 registration statement remains pending SEC approval according to regulatory filings. Investors will closely monitor MiniMed's ability to execute its product roadmap and achieve operational profitability amid competitive pressures in the diabetes technology sector as analysts note.